The first medication for obstructive sleep apnea has been approved by the U.S. Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound ...

Sleep apnea, a widespread health issue, causes breathing interruptions during sleep, leading to oxygen deprivation and various health problems. It manifests in obstructive, central, and mixed forms.

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication to treat obstructive sleep apnea, per a Food and Drug ...

including snoring and obstructive sleep apnea. Obstructive sleep apnea is when a person stops breathing five or more times per hour. When breathing stops, it can lower oxygen levels, affecting the ...

A recent study has found a surprising connection between sleep-related breathing problems and changes in the brain. Published ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

Sleep apnea is known to wreak havoc with the body, contributing to heart problems, diabetes and liver disease. The sleep disorder also appears to have direct effects on brain health, a new study ...

The Food and Drug Administration approved Zepbound as the first prescription medicine to treat sleep apnea on Friday—marking a significant win for the drug company Eli Lilly, which had Zepbound ...